Levine S J, Masur H, Gill V J, Feuerstein I, Suffredini A F, Brown D, Lane H C, Yarchoan R, Shelhamer J H, Ognibene F P
Critical Care Medicine, Microbiology Department, Warren G. Magnuson Clinical Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Am Rev Respir Dis. 1991 Oct;144(4):760-4. doi: 10.1164/ajrccm/144.4.760.
This study assessed the effect of aerosolized pentamidine prophylaxis on the clinical presentation and diagnostic sensitivity of induced sputum examination for Pneumocystis carinii pneumonia. Between January 1, 1988 and October 27, 1990, 348 induced sputum examinations were performed as the initial diagnostic procedure for P. carinii pneumonia in patients infected with the human immunodeficiency virus (HIV). Medical records were reviewed for all induced sputum examinations, and the study group consisted of patients who either had not received prophylactic therapy (n = 193) or had received aerosolized pentamidine prophylaxis (n = 126). A total of 29 induced sputum examinations in patients receiving either other prophylactic regimens or ongoing therapy for previously documented P. carinii pneumonia were excluded from the study group. A total of 72 consecutive episodes of P. carinii pneumonia were subsequently documented by induced sputum examination (n = 54), bronchoalveolar lavage (n = 16), thoracocentesis (n = 1), or autopsy (n = 1). A total of 44 episodes occurred in patients who had not received antipneumocystis prophylaxis, and 28 episodes occurred in patients who had received aerosolized pentamidine. Of patients capable of producing a sputum specimen for analysis, induced sputum examination had a significantly lower diagnostic yield of 64.3% in patients who had received aerosolized pentamidine prophylaxis compared with 92.3% in patients who did not receive prophylaxis (p less than 0.02, Fisher's exact test). When the data were analyzed on an intention to treat basis, although there was a trend suggesting a lower overall yield in the aerosolized pentamidine patients, the difference was not statistically significant (64.3 versus 81.8%, p = 0.17, Fisher's exact test).(ABSTRACT TRUNCATED AT 250 WORDS)
本研究评估了雾化喷他脒预防对卡氏肺孢子虫肺炎临床表现及诱导痰检查诊断敏感性的影响。在1988年1月1日至1990年10月27日期间,对348例感染人类免疫缺陷病毒(HIV)的患者进行了诱导痰检查,作为卡氏肺孢子虫肺炎的初始诊断程序。回顾了所有诱导痰检查的病历,研究组包括未接受预防性治疗的患者(n = 193)或接受雾化喷他脒预防的患者(n = 126)。共有29例接受其他预防方案或针对先前确诊的卡氏肺孢子虫肺炎进行持续治疗的患者的诱导痰检查被排除在研究组之外。随后通过诱导痰检查(n = 54)、支气管肺泡灌洗(n = 16)、胸腔穿刺术(n = 1)或尸检(n = 1)共记录了72例连续的卡氏肺孢子虫肺炎发作。未接受抗肺孢子虫预防的患者共发生44例,接受雾化喷他脒的患者发生28例。在能够咳出用于分析的痰标本的患者中,接受雾化喷他脒预防的患者诱导痰检查的诊断阳性率显著低于未接受预防的患者,分别为64.3%和92.3%(p<0.02,Fisher精确检验)。当基于意向性治疗分析数据时,尽管有趋势表明雾化喷他脒组的总体阳性率较低,但差异无统计学意义(64.3%对81.8%,p = 0.17,Fisher精确检验)。(摘要截短为250字)